General discussion, page-11389

This video is worth watching. It is very short but you can see how smart the BOD is. In summary, the Nasdaq Biotech is seen as oversold relative to the S&P 500. The view is that we will see some strong catalysts that should see the Biotech index double in the next few years. What perfect timing for IHL - a prospective positive OSA trial result , a U.S marketing effort and opening the doors for what will likely be a very hot sector.

https://www.msn.com/en-us/money/careersandeducation/the-nasdaq-biotech-index-could-double-in-the-next-few-years-says-anastasia-amoroso/vi-AASqq4H



Having said that, it doesn't really matter as positive OSA results puts IHL on the path to corporate action - which is not stock market pricing but values on a commercial basis. Exactly where we want to be!

A great buying window ATM that I don't think will last long. Congrats to the BOD again for a fantastic strategic move.